G1 Therapeutics Performance
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
The firm owns a Beta (Systematic Risk) of 0.63, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, G1 Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding G1 Therapeutics is expected to be smaller as well. G1 Therapeutics today owns a risk of 0.0%. Please check out G1 Therapeutics value at risk, and the relationship between the information ratio and kurtosis , to decide if G1 Therapeutics will be following its current price history.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days G1 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong technical indicators, G1 Therapeutics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 94.7 M |
GTHX |
G1 Therapeutics Relative Risk vs. Return Landscape
If you would invest 715.00 in G1 Therapeutics on September 22, 2024 and sell it today you would earn a total of 0.00 from holding G1 Therapeutics or generate 0.0% return on investment over 90 days. G1 Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than GTHX, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
G1 Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for G1 Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as G1 Therapeutics, and traders can use it to determine the average amount a G1 Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| GTHX |
Based on monthly moving average G1 Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of G1 Therapeutics by adding G1 Therapeutics to a well-diversified portfolio.
G1 Therapeutics Fundamentals Growth
GTHX Stock prices reflect investors' perceptions of the future prospects and financial health of G1 Therapeutics, and G1 Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GTHX Stock performance.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.77) % | |||
| Operating Margin | (0.21) % | |||
| Current Valuation | 364.46 M | |||
| Shares Outstanding | 52.76 M | |||
| Price To Earning | (1.95) X | |||
| Price To Book | 15.34 X | |||
| Price To Sales | 6.48 X | |||
| Revenue | 82.51 M | |||
| EBITDA | (39.01 M) | |||
| Cash And Equivalents | 143.96 M | |||
| Cash Per Share | 3.37 X | |||
| Total Debt | 57.17 M | |||
| Debt To Equity | 1.24 % | |||
| Book Value Per Share | 0.47 X | |||
| Cash Flow From Operations | (38.34 M) | |||
| Earnings Per Share | (0.86) X | |||
| Total Asset | 121.54 M | |||
| Retained Earnings | (779.99 M) | |||
| Current Asset | 252.33 M | |||
| Current Liabilities | 9.86 M | |||
About G1 Therapeutics Performance
Evaluating G1 Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if G1 Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if G1 Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina. G1 Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 148 people.Things to note about G1 Therapeutics performance evaluation
Checking the ongoing alerts about G1 Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for G1 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| G1 Therapeutics is not yet fully synchronised with the market data | |
| G1 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82.51 M. Net Loss for the year was (47.97 M) with profit before overhead, payroll, taxes, and interest of 47.55 M. | |
| G1 Therapeutics currently holds about 143.96 M in cash with (38.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37. |
- Analyzing G1 Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether G1 Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining G1 Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating G1 Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of G1 Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of G1 Therapeutics' stock. These opinions can provide insight into G1 Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |